who reports todayUS earnings, drawn as flowsMy portfolio

← Who reports today · Health Care

TECH · Q4 FY2026

Archived report (Q4 FY2026). Latest deep dive →

US GAAP, Q4 FY26 · quarter ended 06/30/2026 (fiscal year is shifted) · released Aug 12

Net earnings

$54.6M

Net sales

$321M

up 1.3% y/y

Operating income

$74.3M

Gross margin

$211M

up 6.3% y/y

The quarter in brief

Revenue grew 1.3% y⁠/⁠y to $321M, operating margin 23.1% vs 7.5%, net income $55M.

All figures in $M.

Sankey diagram of TECH earnings report for Q4 FY2026: revenue, costs and profitNet sales$321 · +1.3%Cost of sales$110 · −7.1%Gross margin$211 · +6.3%65.8% marginSelling, generalandadministrative$113 · −42.4%Research anddevelopment$23.9 · −8.0%Operating income$74.3 · vs −$23.923.1% marginOther income(expense)$3.6 · vs $1Earnings beforeincome taxes$70.7 · vs −$22.9Income taxes$16.1 · vs −$5.222.7% effective rateNet earnings$54.6 · vs −$17.7$0.35/sh · 17.0% margin
Sankey diagram of TECH earnings report for Q4 FY2026: revenue, costs and profit
Line itemAmount and change
Net sales$321 · +1.3%
Cost of sales$110 · −7.1%
Gross margin$211 · +6.3% · 65.8% margin
Selling, general and administrative$113 · −42.4%
Research and development$23.9 · −8.0%
Operating income$74.3 · vs −$23.9 · 23.1% margin
Other income (expense)$3.6 · vs $1
Earnings before income taxes$70.7 · vs −$22.9
Income taxes$16.1 · vs −$5.2 · 22.7% effective rate
Net earnings$54.6 · vs −$17.7 · $0.35/sh · 17.0% margin

Verdict: revenue grew 1.3% y/y to $321M, operating margin 23.1% vs 7.5%, net income $55M.

Bio-Techne agreed to be acquired by Merck KGaA for $73 per share in cash, an enterprise value of approximately $11.3 billion.

Source and notation

Source: Bio-Techne press release, 8-K EX-99.1 of 08/12/2026 (SEC EDGAR). Every figure was matched against the income statement in the release and checked against SEC XBRL.

Open as an image: TECH, Q4 FY2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0

Cite / embed this chart

Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).

Credit line
Chart: “TECH Q4 FY2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/tech/q4-fy2026. Licensed under CC BY 4.0.
HTML: image with link and credit
<figure>
  <a href="https://whoreportstoday.com/t/tech/q4-fy2026"><img src="https://whoreportstoday.com/t/tech/q4-fy2026/sankey.png" alt="TECH Q4 FY2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a>
  <figcaption>Source: <a href="https://whoreportstoday.com/t/tech/q4-fy2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption>
</figure>
Direct link to the image (PNG)
https://whoreportstoday.com/t/tech/q4-fy2026/sankey.png
Link for your article text
<a href="https://whoreportstoday.com/t/tech/q4-fy2026">TECH Q4 FY2026 earnings chart (Who Reports Today)</a>

This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.

TECH — a life science tools company that develops and sells research reagents, protein analysis instruments, diagnostic controls and assays, and tissue-based spatial biology tools to researchers, drug developers and clinical labs.

It makes money in two segments: Protein Sciences and Diagnostics and Spatial Biology. · Source: annual report (Form 10-K, SEC)

More reports: TMO · Q3 2026 · UHS · Q3 2026 · UNH · Q3 2026 · VEEV · Q2 FY2027 · VRTX · Q3 2026 · VTRS · Q3 2026 · WAT · Q3 2026 · WST · Q3 2026 · ZBH · Q3 2026 · ZTS · Q3 2026 · all reports

Company reports

Q1 FY2027latest breakdownNet sales grew 4.6% y/y to $299.7M
Q4 FY2026Revenue grew 1.3% y/y to $321M, operating margin 23.1% vs 7.5%, net income $55M.

Cookies the site needs and, with your consent, Google Analytics — privacy policy